David Ashley, MBBS, PhD

Professor of Neurosurgery
Rory David Deutsch Distinguished Professor of Neuro-Oncology
Professor of Medicine
Professor in Pediatrics
Professor in Pathology
Member of the Duke Cancer Institute
Campus mail 203 Research Dr Msrb1, Box 2600, Durham, NC 27710
Phone (919) 684-4164
Email address david.ashley@duke.edu

Dr. Ashley's primary research focus is laboratory based, investigating the role of immunotherapy as a novel approach to the treatment of tumors of the central nervous system (CNS). Since beginning his appointment at the faculty level at Duke in August of 1995 his activities have centered on two main areas of investigation. The first involves both in vivo and in vitro studies of the use of molecular therapeutics to target a CNS tumor associated antigen. The second area of interest comprises a detailed analysis of the role of TGF beta, a protein messenger produced by tumors of the CNS, both in the pathogenesis of disease and as a possible target for immunotherapy.

In addition to his laboratory role Dr. Ashley is involved in the design and application of a variety of clinical research protocols in the treatment of children with malignant brain tumors.

Education and Training

  • Ph.D., University of Melbourne (Australia), 1998
  • M.B.B.S., University of Melbourne (Australia), 1994
  • F.R.A.C.P., Royal Australasian College of Physicians (Australia), 1993

Publications

Srinivasan, Ethan S., Aaron C. Tan, Carey K. Anders, Ann Marie Pendergast, Dorothy A. Sipkins, David M. Ashley, Peter E. Fecci, and Mustafa Khasraw. “Salting the Soil: Targeting the Microenvironment of Brain Metastases.” Mol Cancer Ther 20, no. 3 (March 2021): 455–66. https://doi.org/10.1158/1535-7163.MCT-20-0579.

PMID
33402399
Full Text

Gromeier, Matthias, Michael C. Brown, Gao Zhang, Xiang Lin, Yeqing Chen, Zhi Wei, Nike Beaubier, et al. “Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy.” Nat Commun 12, no. 1 (January 13, 2021): 352. https://doi.org/10.1038/s41467-020-20469-6.

PMID
33441554
Full Text

Lee, Jessica W., John P. Kirkpatrick, Frances McSherry, James E. Herndon, Eric S. Lipp, Annick Desjardins, Dina M. Randazzo, et al. “Adjuvant Radiation in Older Patients With Glioblastoma: A Retrospective Single Institution Analysis.” Front Oncol 11 (2021): 631618. https://doi.org/10.3389/fonc.2021.631618.

PMID
33732649
Full Text

Finlay, Jonathan, Martin Mynarek, Girish Dhall, Claire Mazewski, Richard Grundy, Bruce H. Cohen, Giles Robinson, et al. “CHEMOTHERAPY STRATEGIES FOR YOUNG CHILDREN NEWLY DIAGNOSED WITH CLASSIC (CLMB) OR ANAPLASTIC/LARGE CELL (A/LCMB) MEDULLOBLASTOMA UP TO THE ERA OF MOLECULAR PROFILING - A COMPARATIVE OUTCOMES ANALYSIS.” In Neuro Oncology, 22:396–97, 2020.

Scholars@Duke

Hariharan, Seethalakshmi, Cem Kilic, Michelle Bowie, Zachary Reitman, and David Ashley. “EPIGENETIC REPROGRAMMING LEADS TO INNATE IMMUNE PATHWAY ACTIVATION IN AT/RT.” In Neuro Oncology, 22:279–279, 2020.

Scholars@Duke

Landi, Daniel, Gary Archer, Timothy Driscoll, Eric Lipp, Bridget Archambault, Eric Thompson, Charlene Flahiff, et al. “CMV PP65 RNA-PULSED DENDRITIC CELL VACCINES FOR PEDIATRIC GLIOBLASTOMA AND MEDULLOBLASTOMA: PHASE I TRIAL RESULTS.” In Neuro Oncology, 22:306–306, 2020.

Scholars@Duke

Mosaheb, Mubeen, Daniel Landi, Elena Dobrikova, Michael Brown, Yuanfan Yang, Jana Cable, Hideho Okada, et al. “GENETICALLY STABLE POLIOVIRUS VECTOR CARRYING H3.3K27M ANTIGEN FOR TREATMENT OF DIFFUSE MIDLINE GLIOMA BY INTRAMUSCULAR INJECTION.” In Neuro Oncology, 22:472–472, 2020.

Scholars@Duke

Cohen, Kenneth, Susan Chi, Cynthia Hawkins, Fausto Rodriguez, Wendy London, Robert Craig Castellino, Dolly Aguilera, et al. “PILOT STUDY OF A SURGERY AND CHEMOTHERAPY-ONLY APPROACH IN THE UPFRONT THERAPY OF CHILDREN WITH WNT-POSITIVE STANDARD RISK MEDULLOBLASTOMA: UPDATED OUTCOMES.” In Neuro Oncology, 22:393–94, 2020.

Scholars@Duke

Finlay, Jonathan L., Martin Mynarek, Girish Dhall, Lucie Lafay-Cousin, Claire Mazewski, David Ashley, Sarah Leary, et al. “CHEMOTHERAPY STRATEGIES FOR YOUNG CHILDREN NEWLY DIAGNOSED WITH DESMOPLASTIC/EXTENSIVE NODULAR MEDULLOBLASTOMA UP TO THE ERA OF MOLECULAR PROFILING - A COMPARATIVE OUTCOMES ANALYSIS OF PROSPECTIVE MULTI-CENTER EUROPEAN AND NORTH AMERICAN TRIALS.” In Neuro Oncology, 22:392–392, 2020.

Scholars@Duke

Chandramohan, Vidyalakshmi, Tyler Evangelous, Eric S. Lipp, Bhavna Hora, Darell D. Bigner, Roger E. McLendon, and David M. Ashley. “ANALYSIS OF IMMUNE SIGNATURES IN PEDIATRIC GLIOBLASTOMAS FOR PATIENT STRATIFICATION TO IMMUNOTHERAPY.” In Neuro Oncology, 22:365–365, 2020.

Scholars@Duke

Pages